Removal of prion infectivity by affinity ligand chromatography during OctaplasLG ® manufacturing - results from animal bioassay studies

Vox Sanguinis

Volumn 102, Issue 4, 2012, Pages 294-301

  Heger, A ^a   Bailey, A ^b   Neisser Svae, A ^c   Ertl, M ^b   Romisch J ^a   Svae, T E ^c  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

^b ViruSure GmbH   (Austria)

^c Octapharma AG   (Switzerland)

Author keywords

Fresh frozen plasma; Pathogen removal; Plasma derivatives; Prion affinity gel; Transfusion transmissible infections

Indexed keywords

PRION PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CONTROLLED STUDY; DISEASE TRANSMISSION; HAMSTER; MALE; MICROSOME; NONHUMAN; PRION; PRIORITY JOURNAL; REPRODUCIBILITY; SCRAPIE; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; WESTERN BLOTTING;

ANIMALS; BLOOD TRANSFUSION; BRAIN; CHROMATOGRAPHY, AFFINITY; CRICETINAE; PLASMA; PRIONS; PROTEIN BINDING;

EID: 84859851244     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01563.x     Document Type: Article

References (20)

1. Brown P: Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007; 13:33-40
2. Peden A, McCardle L, Head MW, et al. : Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16:296-304
3. Cervenakova L, Yakovleva O, McKenzie C, et al. : Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongioform encephalopathy. Transfusion 2003; 43:1687-1694
4. Brown P, Cervenáková L, McShane LM, et al. : Further studies of blood infectivity in an experimental model of transmissible spongioform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
5. Dobra SA, Bennett PG: vCJD and blood transfusion: risk assessment in the United Kingdom. Transfus Clin Biol 2006; 13:307-311
6. Gregori L, Yang H, Anderson S: Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; DOI:
7. Sc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97:219-225
8. ®. Vox Sang 2009; 97:226-233
9. Hammond D, Lathrop J, Cervenakova L, et al. : Prion protein ligand and methods of use U.S. patent WO 2004/050851A2. 2003 Dec 3
10. CPMP/BWP/CPMP/5136/03. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. Committee for Medicinal products for Human Use, European Medicines Agency, 2004
11. CPMP/BWP/CPMP/268/95. Note for guidance on virus validation studies: the design, contribution, and interpretation of studies validating the inactivation and removal of viruses. Committee for Medicinal products for Human Use, European Medicines Agency, 2004
12. Vey M, Baron H, Weiner T, et al. : Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002; 30:187-196
13. Foster PR, Griffin BD, Bienek C, et al. : Distribution of a bovine spongioform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 2004; 86:92-99
14. Stucki M, Boschetti N, Schäfer W, et al. : Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008; 36:239-247
15. Yunoki M, Tanaka H, Urayana T, et al. : Prion removal by nanofiltration under different experimental conditions. Biologicals 2008; 36:27-36
16. Lee DC, Stenland CJ, Miller JL, et al. : A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41:449-455
17. Gregori L, Maring JA, MacAuley C, et al. : Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004; 32:1-10
18. Millson GC, Hunter GD, Kimberlin RH: An experimental examination of the scrapie agent in cell membran mixtures. J Com Pathol 1971; 81:255-265
19. Gregori L, Gurgel PV, Lathrop JT, et al. : Reduction of infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368:2226-2230
20. Gregori L, Lambert BC, Gurgel PV, et al. : Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion affinity ligands. Transfusion 2006; 46:1152-1161